Breaking News

ValenzaBio, ProBioGen Enter Cell Line Pact

Aims to maximize cell line productivity leveraging ProBioGen's GlymaxX technology for ValenzaBio's clinical-stage antibody.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen and ValenzaBio have initiated a cell line development project involving the application of ProBioGen’s GlymaxX technology.   ProBioGen will generate a new CHO-based expression system for ValenzaBio’s VB119, a clinical-stage antibody. In addition to the CHO.RiGHT cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology. GlymaxX enables a fine tuning of the fucose content of the antibody towards the originator molecule’s fucose conte...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters